Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

Highlighted Agenda

Check back later this month for the complete agenda

Joint Keynote: The Era of Data Enlightenment
The Impact of Innovation on Market Access
  • Better: Empower R&D to differentiate your company through innovation in the time of tighter access requirements
  • Faster: Streamline your development process with more payer interactions earlier in the process
  • Smarter: Create higher quality, fluid and adaptable evidence packages

Janssen Steve Wooding Head, Global Commercial and Market Access Strategy Organisation Janssen

Panel: Shape transition to a data-led world with external education, collaboration and partnership
  • Build trust in real-world evidence (RWE) amongst regulators and payers with consistent behaviour across the industry
  • Reshape public perception of data use to make data sharing the new norm
  • Unleash Europe’s real-world study possibilities by aiding the advancement of data linkage capabilities

Takeda Isabel Torres Vice President Market Access, Public Affairs and Patient Advocacy for Europe and Canada Takeda

NIHR Sheila McCorkindale Manchester Lead, Key Primary Care Advisor GSK NIHR

sanofi Chris Chinn Head of Real World Investigations Sanofi

Further speakers TBC

Making change happen: How NICE is working with system partners to support uptake and improve patient care
  • Build bridges with system partners to ensure a better flow of information to provide all parties with relevant and up to date information
  • Increase uptake through open discussions with government bodies that will help you craft the best drugs for the market
  • Ensure patient concerns are incorporated as a core objective in all decisions and projects

NICE Professor Gillian Leng Deputy Chief Executive NICE

Payer & HTA Roundtables introducing Access Allies
  • Prove performance with innovative pricing mechanisms in Belgium
  • Understand the private payer model in France
  • Italian innovation: Performance pricing models to gain reimbursement
  • How to create win-win situations in contracts between payers and pharma companies?
  • The use of real-world evidence to inform drug pricing and reimbursement decisions in Canada – pharma perceptions, current platforms, barriers and limitations, and future developments.
Grow the foundations of trust in RWD
Case study: The new federated EHR technology approach –  the case of InSite hospital network in Europe
  • Understand how the InSite EHR platform is enhancing protocol design and patient recruitment across Europe
  • Learn how both industry and health care can benefit from EHR enabled services
  • See how understanding of the full stakeholder environment involved enables optimum use of EHRs

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Health Care Partner TBC

Use real-world data to satisfy regulatory pathways for label change
  • Hear about developments in the European and U.S. regulatory spaces around the use of RWD
  • Learn how this is providing increased transparency and opportunity for use of such data to expand drug labels
  • Understand the current limitations for potential label change based on such data sources

Astellas Billy Franks Senior Director, Head of Analytics, Real-World Informatics Astellas

Enable value-based pricing with the predictive power of real-world evidence
  • Enhance the value of post-registrational evidence with the use of predictive analytics
  • Create multi-stakeholder partnerships founded on new insights allowing for sustainable access
  • Understand the mid–long term private–public partnerships and risk-sharing needed to improve the lifetime profile of certain diseases

Takeda Ioannis Petrakis Global GI Market Access Head Takeda

Panel: Explore the differences in RWE assessment between different European regulatory and payer bodies
  • See where RWE fits into the overall evidence hierarchy amongst a number of key European assessment agencies
  • Understand how to tailor your evidence generation strategy to account for the differences in preference between organisations

Eli Lilly Enkeleida Nikai Director of Real World Evidence Eli Lilly

Bayer Stefan Schröder VP, Head of Data Generation & Business Excellence Bayer

Further speakers TBC

Understand how to demonstrate real-world effectiveness to the European Medical Agency (EMA)
  • See how the Adaptive Pathways pilot programme has created the foundations of a “common evidence base” between regulators and HTA
  • Meet the needs of both HTAs and regulators with a long-term RWE generation plan from day 1, bolstering RCT efficacy findings
  • Explore the next steps in developing a “gold standard” of RWD required to meet EMA quality and reliability assessment requirements

Speaker TBC

Empower internal functions
Build a framework for considering RWE as part of Integrated Brand Planning
  • Learn how to better demonstrate effectiveness of marketed products to support RCTs
  • Understand how to identify and present data generation needs from a recent Bayer implementation example
  • Explore how RWE methodology differs for a given therapeutic area and/or brand

Bayer Shurjeel Choudhri SVP and Head, Medical & Scientific Affairs Bayer

Turn education into implementation: Increase adoption of real-world studies across internal business functions
  • Accelerate internal RWE use with a move past terminology education to capability training excellence
  • Build leadership and skills in teams throughout your organisation to successfully enact independent real-world studies

Sanofi David Williams RWE Lead for Consumer Health Care and General Medicine and Emerging Markets Sanofi

Optimise the development of RWE brand strategies
  • Build comprehensive evidence generation plans with end results front of mind
  • Combine global and affiliate led strategic approaches to develop balanced RWE strategies
  • Implement RWE solutions and sharing available evidence

Eli Lilly Enkeleida Nikai Director of Real World Evidence Eli Lilly

Finding the pragmatic solution
Case Study: Explore how AstraZeneca’s pioneering pragmatic RWD studies are influencing regulatory decision-making
  • Understand how the study design incorporated a range of RWD sources to assess the outcomes of 300,000+ patients internationally
  • See how payer and regulatory decision-making has been accelerated by the successful findings of the type 2 diabetes study

AstraZeneca Sajan Khosla Head of Real World Evidence - Centre of Excellence, Medical Evidence & Observational Research AstraZeneca

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Panel: Accelerate the adoption of pragmatic trials in Europe
  • Build internal confidence in pragmatic studies with understanding of long-term capabilities required to run trials more cost-effectively
  • Understand best practise study design variables to more effectively gain accurate real world results
  • Explore the collaborative undertaking required with the full stakeholder environment to meet operational capability requirements
  • Maintain full transparency by building patient education and consent programs into study design

AstraZeneca Sajan Khosla Head of Real World Evidence - Centre of Excellence, Medical Evidence & Observational Research AstraZeneca

NIHR Clinical Research Network Martin Gibson Director Greater Manchester NIHR Clinical Research Network

Swedish Association of Local Authorities and Regions Tina Lidén Mascher Strategist, International Registry Projects and Collaborations Swedish Association of Local Authorities and Regions

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Unlock novel insights with the next generation of technological capabilities
Learn how to build an operational and user-friendly RWE platform
  • Understand the complexities of modelling Real-World Data and how an enterprise multi-model database solves this challenge
  • Connecting graph-based data such as ICD taxonomies with Patient Electronic Data Records
  • Creating a flexible platform to easily add and combine new data sources

MarkLogic Sasha Mitrovich Principal Sales Engineer MarkLogic

MarkLogic Bill Fox, JD, MA CTO, Healthcare, Life Sciences and Insurance MarkLogic

Case study: Federated networks: the gateway to cross regional real-world evidence – learning from EMIF and looking towards EHDN (European Health Data Network)
  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • Understand how to meet the needs of multiple stakeholders through key actor collaboration

Janssen Nigel Hughes Scientific Director Janssen

Panel: Generate high quality RWD during clinical trials leveraging the latest wave of digital health tools
  • Map and evaluate the myriad providers to ensure investment leads to meeting evidence generation needs
  • Ensure data impact through early communication with regulators, HTAs and payers to increase relevance and quality
  • Work with patients to maximise personal device use and improve data intake with understanding of device potential pitfalls and perceived benefits
  • Use proof-of-concept trials to reduce investment risk with greater understanding of product real-life performance

Merck KGaA Merat Bagha Director of Marketing, Digital Health & Patient Care Business Merck KGaA

UCB Hervé Dumas Patient Care Solutions Lead UCB

Further speakers TBC

Joint Keynote: The Era of Data Enlightenment
The Impact of Innovation on Market Access
  • Better: Empower R&D to differentiate your company through innovation in the time of tighter access requirements
  • Faster: Streamline your development process with more payer interactions earlier in the process
  • Smarter: Create higher quality, fluid and adaptable evidence packages

Janssen Steve Wooding Head, Global Commercial and Market Access Strategy Organisation Janssen

Panel: Shape transition to a data-led world with external education, collaboration and partnership
  • Build trust in real-world evidence (RWE) amongst regulators and payers with consistent behaviour across the industry
  • Reshape public perception of data use to make data sharing the new norm
  • Unleash Europe’s real-world study possibilities by aiding the advancement of data linkage capabilities

Takeda Isabel Torres Vice President Market Access, Public Affairs and Patient Advocacy for Europe and Canada Takeda

NIHR Sheila McCorkindale Manchester Lead, Key Primary Care Advisor GSK NIHR

sanofi Chris Chinn Head of Real World Investigations Sanofi

Further speakers TBC

Making change happen: How NICE is working with system partners to support uptake and improve patient care
  • Build bridges with system partners to ensure a better flow of information to provide all parties with relevant and up to date information
  • Increase uptake through open discussions with government bodies that will help you craft the best drugs for the market
  • Ensure patient concerns are incorporated as a core objective in all decisions and projects

NICE Professor Gillian Leng Deputy Chief Executive NICE

Payer & HTA Roundtables introducing Access Allies
  • Prove performance with innovative pricing mechanisms in Belgium
  • Understand the private payer model in France
  • Italian innovation: Performance pricing models to gain reimbursement
  • How to create win-win situations in contracts between payers and pharma companies?
  • The use of real-world evidence to inform drug pricing and reimbursement decisions in Canada – pharma perceptions, current platforms, barriers and limitations, and future developments.
Access: The early bird always wins
Panel: Take early access mainstream: Explore how early access can support your drug development programme
  • Gain a sound understanding of the early access environment, evaluate unmet need and the potential assets to meet this need and set the right precedent for a full-scale launch
  • Learn how to formulate the best launch plan in concert with the patient ecosystem and payers
  • Utilize early access data to support your clinical development plan by tailoring R&D, H2H studies and health economics outcomes
  • Understand the reimbursement options and possibilities at the EU level and what payers need in order to recognise value beyond efficacy in clinical studies

European Confederation of Pharmaceutical Entrepreneurs Dr. Alexander Natz Secretary-General European Confederation of Pharmaceutical Entrepreneurs

UCB Florence Penicaud Head of Market Access, Switzerland UCB

GSK Sebastien Le Roux VP & Head of Global Market Access GSK

Lundbeck Pernille Storm Global Market Access Director, Neurology Lundbeck

Develop an integrated strategy for evidence generation in Rare Diseases
  • Ensure the right clinical data set is in place during the EMA’s period of evaluation, taking into consideration any evidence gaps
  • How to anticipate payer requirements earlier and prepare an evidence package to support your product’s value
  • Set out the core development of Real World Data required to guarantee and maintain drugs access and patient outcomes

CSL Behring Lara Pippo Head of Market Access CSL Behring

Value for money, money for value: the science behind reimbursement
Panel: Differentiate between payers and meet individual needs for better access
  • Incorporate the local & national payer perspective early in the drug development lifecycle to support commercialisation post-launch
  • Understand how your therapy will fit into or change current and future treatment paradigms
  • Develop a product strategy that leverages the current and future health delivery system and infrastructure for successful therapy uptake

AXA Charles De Cidrac Director of Health AXA

The cures are coming: How to secure market access for high-value drugs
  • Understand that the emergence of curative treatments requires innovative payment models for market access
  • Get data on the global pipeline for “cures” and estimates for budget impact
  • Learn about payer perspectives on payment models for “cures”

RAND Soeren Mattke Managing Director RAND

The future of pricing
Improve access through innovative pricing models
  • Navigate the access challenges associated with alternative pricing schemes for expanded therapy uptake
  • Review the alternative payment model spectrum and position your company in a regime measured by performance and outcomes
  • Understand the European appetite for pricing schemes and build models which payers will want to buy into

Roche Esther Haik Regional Market Access Roche

Personalised reimbursement models: Mission impossible?
  • A fresh look at the reimbursement and pricing environment for combination pricing and the opportunities for improved access
  • Addressing the information gap: A critical look at the infrastructure needed to capture usage, compliant with data privacy and enable payment of differentiated prices
  • An analysis of the significant milestones and setbacks reached with personalised reimbursement models in Europe

Merck Group Marco Rauland Global Head Pricing & Payer Excellence Merck Group

The path to a healthy healthcare system
Produce the best product for patients, not just payers
  • Meet the needs of all stakeholders, not just payers, by engaging with them during development
  • Market your product correctly by understanding how the funding pathway differs from country to country
  • Map the entire patient journey, identify pressure points and create a product that meets the most pressing needs of both physicians and patients

Sanofi Nazanin Mehin Global Head Value & Access Cardiovascular Sanofi

Case Study: Take an active part in the healthcare system: The Novo-Nordisk story
  • Hear how Novo-Nordisk is working creatively with health authorities, developing unique solutions to optimise the digital patient journey
  • Foster productive partnerships with healthcare systems and create joint responsibility on health outcomes
  • Encourage a transparent and win-win approach - seek collaboration initiatives that improve patient outcomes, and secure healthy growth for your own business

Novo Nordisk Marta Carrera Market Access & Public Affairs Director Novo Nordisk

Panel: Healthcare out of the hospital and into the patient’s home
  • Tap into strategic partnerships, which will improve patient satisfaction and optimise overall patient care
  • Position industry as a credible expert and best partner to stimulate innovation, efficiency and better service design
  • Plug healthcare gaps and alleviate capacity constraints in the health economy to optimise health gains and reduce health inequalities

Bayer Amanda Cunnington Head of Market Access Bayer

UCB Mata Charokopou Market Access & Patient Value Lead UCB

Celgene Jessica Leygues Patient Advocacy Lead Celgene

Joint Keynote: The Era of Data Enlightenment
The Impact of Innovation on Market Access
  • Better: Empower R&D to differentiate your company through innovation in the time of tighter access requirements
  • Faster: Streamline your development process with more payer interactions earlier in the process
  • Smarter: Create higher quality, fluid and adaptable evidence packages

Janssen Steve Wooding Head, Global Commercial and Market Access Strategy Organisation Janssen

Panel: Shape transition to a data-led world with external education, collaboration and partnership
  • Build trust in real-world evidence (RWE) amongst regulators and payers with consistent behaviour across the industry
  • Reshape public perception of data use to make data sharing the new norm
  • Unleash Europe’s real-world study possibilities by aiding the advancement of data linkage capabilities

Takeda Isabel Torres Vice President Market Access, Public Affairs and Patient Advocacy for Europe and Canada Takeda

NIHR Sheila McCorkindale Manchester Lead, Key Primary Care Advisor GSK NIHR

sanofi Chris Chinn Head of Real World Investigations Sanofi

Further speakers TBC

Making change happen: How NICE is working with system partners to support uptake and improve patient care
  • Build bridges with system partners to ensure a better flow of information to provide all parties with relevant and up to date information
  • Increase uptake through open discussions with government bodies that will help you craft the best drugs for the market
  • Ensure patient concerns are incorporated as a core objective in all decisions and projects

NICE Professor Gillian Leng Deputy Chief Executive NICE

Payer & HTA Roundtables introducing Access Allies
  • Prove performance with innovative pricing mechanisms in Belgium
  • Understand the private payer model in France
  • Italian innovation: Performance pricing models to gain reimbursement
  • How to create win-win situations in contracts between payers and pharma companies?
  • The use of real-world evidence to inform drug pricing and reimbursement decisions in Canada – pharma perceptions, current platforms, barriers and limitations, and future developments.

Download your event brochure

Full speaker list • Full conference agenda • Audience breakdown

Grow the foundations of trust in RWD
Case study: The new federated EHR technology approach –  the case of InSite hospital network in Europe
  • Understand how the InSite EHR platform is enhancing protocol design and patient recruitment across Europe
  • Learn how both industry and health care can benefit from EHR enabled services
  • See how understanding of the full stakeholder environment involved enables optimum use of EHRs

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Health Care Partner TBC

Use real-world data to satisfy regulatory pathways for label change
  • Hear about developments in the European and U.S. regulatory spaces around the use of RWD
  • Learn how this is providing increased transparency and opportunity for use of such data to expand drug labels
  • Understand the current limitations for potential label change based on such data sources

Astellas Billy Franks Senior Director, Head of Analytics, Real-World Informatics Astellas

Enable value-based pricing with the predictive power of real-world evidence
  • Enhance the value of post-registrational evidence with the use of predictive analytics
  • Create multi-stakeholder partnerships founded on new insights allowing for sustainable access
  • Understand the mid–long term private–public partnerships and risk-sharing needed to improve the lifetime profile of certain diseases

Takeda Ioannis Petrakis Global GI Market Access Head Takeda

Panel: Explore the differences in RWE assessment between different European regulatory and payer bodies
  • See where RWE fits into the overall evidence hierarchy amongst a number of key European assessment agencies
  • Understand how to tailor your evidence generation strategy to account for the differences in preference between organisations

Eli Lilly Enkeleida Nikai Director of Real World Evidence Eli Lilly

Bayer Stefan Schröder VP, Head of Data Generation & Business Excellence Bayer

Further speakers TBC

Understand how to demonstrate real-world effectiveness to the European Medical Agency (EMA)
  • See how the Adaptive Pathways pilot programme has created the foundations of a “common evidence base” between regulators and HTA
  • Meet the needs of both HTAs and regulators with a long-term RWE generation plan from day 1, bolstering RCT efficacy findings
  • Explore the next steps in developing a “gold standard” of RWD required to meet EMA quality and reliability assessment requirements

Speaker TBC

Empower internal functions
Build a framework for considering RWE as part of Integrated Brand Planning
  • Learn how to better demonstrate effectiveness of marketed products to support RCTs
  • Understand how to identify and present data generation needs from a recent Bayer implementation example
  • Explore how RWE methodology differs for a given therapeutic area and/or brand

Bayer Shurjeel Choudhri SVP and Head, Medical & Scientific Affairs Bayer

Turn education into implementation: Increase adoption of real-world studies across internal business functions
  • Accelerate internal RWE use with a move past terminology education to capability training excellence
  • Build leadership and skills in teams throughout your organisation to successfully enact independent real-world studies

Sanofi David Williams RWE Lead for Consumer Health Care and General Medicine and Emerging Markets Sanofi

Optimise the development of RWE brand strategies
  • Build comprehensive evidence generation plans with end results front of mind
  • Combine global and affiliate led strategic approaches to develop balanced RWE strategies
  • Implement RWE solutions and sharing available evidence

Eli Lilly Enkeleida Nikai Director of Real World Evidence Eli Lilly

Finding the pragmatic solution
Case Study: Explore how AstraZeneca’s pioneering pragmatic RWD studies are influencing regulatory decision-making
  • Understand how the study design incorporated a range of RWD sources to assess the outcomes of 300,000+ patients internationally
  • See how payer and regulatory decision-making has been accelerated by the successful findings of the type 2 diabetes study

AstraZeneca Sajan Khosla Head of Real World Evidence - Centre of Excellence, Medical Evidence & Observational Research AstraZeneca

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Panel: Accelerate the adoption of pragmatic trials in Europe
  • Build internal confidence in pragmatic studies with understanding of long-term capabilities required to run trials more cost-effectively
  • Understand best practise study design variables to more effectively gain accurate real world results
  • Explore the collaborative undertaking required with the full stakeholder environment to meet operational capability requirements
  • Maintain full transparency by building patient education and consent programs into study design

AstraZeneca Sajan Khosla Head of Real World Evidence - Centre of Excellence, Medical Evidence & Observational Research AstraZeneca

NIHR Clinical Research Network Martin Gibson Director Greater Manchester NIHR Clinical Research Network

Swedish Association of Local Authorities and Regions Tina Lidén Mascher Strategist, International Registry Projects and Collaborations Swedish Association of Local Authorities and Regions

AstraZeneca Mats Sundgren Director Health Informatics AstraZeneca

Unlock novel insights with the next generation of technological capabilities
Learn how to build an operational and user-friendly RWE platform
  • Understand the complexities of modelling Real-World Data and how an enterprise multi-model database solves this challenge
  • Connecting graph-based data such as ICD taxonomies with Patient Electronic Data Records
  • Creating a flexible platform to easily add and combine new data sources

MarkLogic Sasha Mitrovich Principal Sales Engineer MarkLogic

MarkLogic Bill Fox, JD, MA CTO, Healthcare, Life Sciences and Insurance MarkLogic

Case study: Federated networks: the gateway to cross regional real-world evidence – learning from EMIF and looking towards EHDN (European Health Data Network)
  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • Understand how to meet the needs of multiple stakeholders through key actor collaboration

Janssen Nigel Hughes Scientific Director Janssen

Panel: Generate high quality RWD during clinical trials leveraging the latest wave of digital health tools
  • Map and evaluate the myriad providers to ensure investment leads to meeting evidence generation needs
  • Ensure data impact through early communication with regulators, HTAs and payers to increase relevance and quality
  • Work with patients to maximise personal device use and improve data intake with understanding of device potential pitfalls and perceived benefits
  • Use proof-of-concept trials to reduce investment risk with greater understanding of product real-life performance

Merck KGaA Merat Bagha Director of Marketing, Digital Health & Patient Care Business Merck KGaA

UCB Hervé Dumas Patient Care Solutions Lead UCB

Further speakers TBC

Access: The early bird always wins
Panel: Take early access mainstream: Explore how early access can support your drug development programme
  • Gain a sound understanding of the early access environment, evaluate unmet need and the potential assets to meet this need and set the right precedent for a full-scale launch
  • Learn how to formulate the best launch plan in concert with the patient ecosystem and payers
  • Utilize early access data to support your clinical development plan by tailoring R&D, H2H studies and health economics outcomes
  • Understand the reimbursement options and possibilities at the EU level and what payers need in order to recognise value beyond efficacy in clinical studies

European Confederation of Pharmaceutical Entrepreneurs Dr. Alexander Natz Secretary-General European Confederation of Pharmaceutical Entrepreneurs

UCB Florence Penicaud Head of Market Access, Switzerland UCB

GSK Sebastien Le Roux VP & Head of Global Market Access GSK

Lundbeck Pernille Storm Global Market Access Director, Neurology Lundbeck

Develop an integrated strategy for evidence generation in Rare Diseases
  • Ensure the right clinical data set is in place during the EMA’s period of evaluation, taking into consideration any evidence gaps
  • How to anticipate payer requirements earlier and prepare an evidence package to support your product’s value
  • Set out the core development of Real World Data required to guarantee and maintain drugs access and patient outcomes

CSL Behring Lara Pippo Head of Market Access CSL Behring

Value for money, money for value: the science behind reimbursement
Panel: Differentiate between payers and meet individual needs for better access
  • Incorporate the local & national payer perspective early in the drug development lifecycle to support commercialisation post-launch
  • Understand how your therapy will fit into or change current and future treatment paradigms
  • Develop a product strategy that leverages the current and future health delivery system and infrastructure for successful therapy uptake

AXA Charles De Cidrac Director of Health AXA

The cures are coming: How to secure market access for high-value drugs
  • Understand that the emergence of curative treatments requires innovative payment models for market access
  • Get data on the global pipeline for “cures” and estimates for budget impact
  • Learn about payer perspectives on payment models for “cures”

RAND Soeren Mattke Managing Director RAND

The future of pricing
Improve access through innovative pricing models
  • Navigate the access challenges associated with alternative pricing schemes for expanded therapy uptake
  • Review the alternative payment model spectrum and position your company in a regime measured by performance and outcomes
  • Understand the European appetite for pricing schemes and build models which payers will want to buy into

Roche Esther Haik Regional Market Access Roche

Personalised reimbursement models: Mission impossible?
  • A fresh look at the reimbursement and pricing environment for combination pricing and the opportunities for improved access
  • Addressing the information gap: A critical look at the infrastructure needed to capture usage, compliant with data privacy and enable payment of differentiated prices
  • An analysis of the significant milestones and setbacks reached with personalised reimbursement models in Europe

Merck Group Marco Rauland Global Head Pricing & Payer Excellence Merck Group

The path to a healthy healthcare system
Produce the best product for patients, not just payers
  • Meet the needs of all stakeholders, not just payers, by engaging with them during development
  • Market your product correctly by understanding how the funding pathway differs from country to country
  • Map the entire patient journey, identify pressure points and create a product that meets the most pressing needs of both physicians and patients

Sanofi Nazanin Mehin Global Head Value & Access Cardiovascular Sanofi

Case Study: Take an active part in the healthcare system: The Novo-Nordisk story
  • Hear how Novo-Nordisk is working creatively with health authorities, developing unique solutions to optimise the digital patient journey
  • Foster productive partnerships with healthcare systems and create joint responsibility on health outcomes
  • Encourage a transparent and win-win approach - seek collaboration initiatives that improve patient outcomes, and secure healthy growth for your own business

Novo Nordisk Marta Carrera Market Access & Public Affairs Director Novo Nordisk

Panel: Healthcare out of the hospital and into the patient’s home
  • Tap into strategic partnerships, which will improve patient satisfaction and optimise overall patient care
  • Position industry as a credible expert and best partner to stimulate innovation, efficiency and better service design
  • Plug healthcare gaps and alleviate capacity constraints in the health economy to optimise health gains and reduce health inequalities

Bayer Amanda Cunnington Head of Market Access Bayer

UCB Mata Charokopou Market Access & Patient Value Lead UCB

Celgene Jessica Leygues Patient Advocacy Lead Celgene

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown

Download the detailed event brochure here